Genetic Predispositions of Glucocorticoid Resistance and Therapeutic Outcomes in Polymyalgia Rheumatica and Giant Cell Arteritis
Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are closely related chronic inflammatory diseases. Glucocorticoids (GCs) are first-choice drugs for PMR and GCA, although some patients show poor responsiveness to the initial GC regimen or experience flares after GC tapering. To date, no v...
Main Authors: | Tomas Smutny, Ivan Barvik, Tomas Veleta, Petr Pavek, Tomas Soukup |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-04-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/8/5/582 |
Similar Items
-
A qualitative study of patient perspectives related to glucocorticoid therapy in polymyalgia rheumatica and giant cell arteritis
by: Hoon E, et al.
Published: (2019-08-01) -
Leukocyte Dynamics Reveal a Persistent Myeloid Dominance in Giant Cell Arteritis and Polymyalgia Rheumatica
by: Yannick van Sleen, et al.
Published: (2019-08-01) -
Possible giant cell arteritis symptoms are common in newly diagnosed patients with Polymyalgia Rheumatica: results from an incident primary care PMR cohort
by: William Masson, et al.
Published: (2017-12-01) -
Widespread headache as the first clinical manifestation of giant cell arteritis in patients affected by polymyalgia rheumatica
by: Ciro Manzo
Published: (2016-11-01) -
The evolution of diagnosis of polymyalgia rheumatica
by: A. M. Satybaldyev
Published: (2019-12-01)